{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:10:58Z","timestamp":1718608258183},"reference-count":16,"publisher":"Wiley","issue":"3-4","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4072,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[1998,3]]},"abstract":"<jats:sec><jats:label \/><jats:p><jats:bold>Summary. <\/jats:bold> In this study, in addition to studying the efficacy and safety of the once\u2010daily administration of 100\u2010mg capsules of fluconazole over an 8\u2010week administration period with six patients with hyperkeratotic\u2010type tinea pedis, we also measured the serum and horny layer concentrations of fluconazole to study the mobility into the horny layer in diseased areas of the sole skin. The final overall efficacy and overall safety were both 100% (six out of six), and no side\u2010effects, including abnormal\u2010laboratory changes, were observed in any of the patients. The drug mobility study revealed that in the horny layer of the skin a steady state was reached after 4 weeks of administration, with the mean concentration being 12.8\u03bcgg<jats:sup>\u20101<\/jats:sup>. This concentration was a high concentration that was no less than 13 times the geometric mean MIC (0.972 \u03bcg ml<jats:sup>\u20101<\/jats:sup>) for fresh clinical isolates of Trichophyton rubrum. Based on the above results, fluconazole is considered to be highly useful for treating various kinds of dermato\u2010mycosis, including hyperkeratotic\u2010type tinea pedis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Zusammenfassung<\/jats:title><jats:p>In der vorliegenden Studie wurde au\u00dfer der Untersuchung der Wirksamkeit und Sicherheit einer einmaligen t\u00e4glichen Dosis in Form von 100 mg Fluconazol\u2010Kapseln \u00fcber einen Zeitraum von 8 Wochen bei 6 Patienten mit hyperkeratotischer Tinea pedis auch die Fluconazol\u2010Konzentration im Serum und in der Hornhautschicht gemessen, um den \u00dcbergang in die Hornhautschicht im Bereich der L\u00e4sionen auf der Fu\u00dfsohle zu untersuchen. Die Gesamtwirksamkeit und Sicherheit betrug jeweils 100% (6\/6), wobei weder Nebenwirkungen noch anormale Laborwerte bei den Patienten beobachtet wurden. Eine Mobilit\u00e4tsstudie zeigte da\u00df nach etwa 4\u2010w\u00f6chiger Behandlung eine Flie\u00dfgleichgewichtskonzentration in der Hornhautschicht erreicht wurde, die durchschnittlich 12.8 \u03bcg g<jats:sup>\u20101<\/jats:sup> betrug. Diese hohe Konzentration betrug nicht weniger als das 13\u2010fache der minimalen Hemmkonzentration MIC (0.972 \u03bcg ml<jats:sup>\u20101<\/jats:sup>) f\u00fcr frische klinische Isolate von Trichophyton rubrum. Diese Ergebnisse belegen, da\u00df Fluconazol bei der Behandlung verschiedener Dermatomykosen, einschlie\u00dflich Tinea pedis, zuverl\u00e4ssig wirksam ist.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1439-0507.1998.tb00317.x","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T17:00:42Z","timestamp":1240592442000},"page":"153-162","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of oral fluconazole in tinea pedis of the hyperkeratotic type. Stratum corneum levels"],"prefix":"10.1111","volume":"41","author":[{"given":"H.","family":"Tanuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Yaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Katsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm1960.27.190"},{"key":"e_1_2_1_3_2","first-page":"1939","article-title":"Treatment of hyperkeratotic tinea pedis","volume":"37","author":"Tanuma H.","year":"1995","journal-title":"Rinso. Derma. (Tokyo)"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1993.tb00987.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1994.tb00788.x"},{"key":"e_1_2_1_6_2","first-page":"687","article-title":"Evaluation committee report on the adverse events judging standard","volume":"39","author":"Kunii O.","year":"1991","journal-title":"Jpn. J. Chemother."},{"key":"e_1_2_1_7_2","first-page":"2599","article-title":"Antimycotic drugs by oral administration","volume":"74","author":"Higashi N.","year":"1992","journal-title":"Ther"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/archderm.1981.01650010022016","article-title":"Griseofulvin\u2010resistant dermatophytosis correlates with in vitro resistance","volume":"117","author":"Artis W. M.","year":"1981","journal-title":"Arch. Dermatol."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm.37.199"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.5.832"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm1960.27.119"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1206"},{"key":"e_1_2_1_13_2","first-page":"3","article-title":"Pharmacokinetic evaluation of fluconazole and plasma, epidermis and blister fluid.","volume":"31","author":"Haneke E.","year":"1992","journal-title":"Int. J. Dermatol."},{"key":"e_1_2_1_14_2","first-page":"127","article-title":"Clinical research on fluconazole for primary pneumomycoses","volume":"42","author":"Nakajima M.","year":"1989","journal-title":"Jpn. J. Antibiol."},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archderm.1972.01620120032006","article-title":"Griseofulvin levels in stratum corneum","volume":"106","author":"Epstein W. L.","year":"1972","journal-title":"Arch. Damatol."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70037-7"},{"key":"e_1_2_1_17_2","first-page":"254","volume-title":"Dermatologie und Venerologie","author":"Steigleder G. K.","year":"1975"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.1998.tb00317.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.1998.tb00317.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T04:01:38Z","timestamp":1693454498000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.1998.tb00317.x"}},"subtitle":["Wirksamkeit oral verabreichten Fluconazols bei hyperkeratotischer Tinea pedis. Stratum corneum\u2010Konzentrationen"],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":16,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["10.1111\/j.1439-0507.1998.tb00317.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.1998.tb00317.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}